Theraclion – About the Company
Theraclion develops, manufactures, and markets EchoPulse®, a non-invasive device for benign tumor removal that is CE marked for breast fibroadenomas and thyroid nodules. There are approximately 1.5 million new cases of these benign tumors each year across Europe, the Middle East, and Africa (EMEA), representing a large market opportunity. Theraclion is actively seeking reimbursement for EchoPulse® in Europe and surrounding territories to support a large-scale commerical launch. Efforts are underway to expand EchoPulse® into additional markets, and clinical data are being collected at the University of Virginia to support US approval.